Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
NT-219 by Purple Biotech for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval
NT-219 is under clinical development by Purple Biotech and currently in Phase II for Recurrent Head And Neck Squamous Cell...
Data Insights
Risk adjusted net present value: What is the current valuation of Purple Biotech's CM-24?
CM-24 is a monoclonal antibody commercialized by Purple Biotech, with a leading Phase II program in Metastatic Adenocarcinoma of The...